Study Comparing the PET Scan and MRI in Identifying Breast Malignancies in Women With Breast Abnormalities
|ClinicalTrials.gov Identifier: NCT00639535|
Recruitment Status : Completed
First Posted : March 20, 2008
Last Update Posted : May 21, 2015
This is a study looking at advanced imaging such as PET/CT and MRI to see if they can provide a more accurate assessment of the patient with dense breasts or difficult to interpret mammograms. In addition, the ability to determine whether one or the other is more accurate or whether both together would be appropriate in this clinical situation, may be able to be measured.
The MRI studies are very sensitive for detection of breast histopathology but less specific in differentiating between small low grade malignancies are more benign pathologies. Multifocal pathology can be challenging in determining site(s) for biopsy.
PET scanning is specific in the measurement of metabolic glucose activity of various histopathologies and is accurate in differentiating aggressive from benign pathology in multifocal breast disease. A further drawback of PET is the lack of ability to observe lesions less than 3-4mm in diameter.
In select cases the combination of MR and PET/CT is able to come to a more conclusive diagnosis - specifically with bilateral or multifocal breast disease.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||56 participants|
|Official Title:||Comparative Study of the Diagnostic Accuracy of Scintimammography (Fluorine 18-FDG PET Scintigraphic Imaging) and Magnetic Resonance Imaging in Identifying Malignant Breast Lesions, In Subjects With Breast Abnormalities|
|Study Start Date :||January 2002|
|Primary Completion Date :||April 2014|
|Study Completion Date :||April 2014|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00639535
|United States, New York|
|Central New York PET Center|
|Liverpool, New York, United States, 13088|
|University Radiology Associates|
|Syracuse, New York, United States, 13202|
|Institute For Human Performance|
|Syracuse, New York, United States, 13210|
|Principal Investigator:||David Feiglin, MD||State University of New York - Upstate Medical University|